AIM ImmunoTech reports Q2 EPS ($3.68) vs ($3.00) last year

As of June 30, 2025, AIM reported cash, cash equivalents and marketable investments of $835,000. “Through the second quarter, we continued to prioritize and accelerate our development efforts for Ampligen, particularly in our Phase 2 trial for locally advanced pancreatic cancer in collaboration with Erasmus Medical Center and AstraZeneca. We remain encouraged by the growing body of positive clinical data demonstrated to date and believe that as we build momentum, we are well positioned to execute on a clear path toward government approval. Pancreatic cancer is one of the most aggressive and difficult-to-treat cancers, and our mission remains focused on making a meaningful difference in this space for patients,” commented AIM Chief Executive Officer Thomas Equels.